Skip to content

Effect of Targeted CA330 on Mortality With in Critically Ill COVID-19 Hemodilysis Patients: a Single-center Clinical Trial

Effect of Targeted CA330 on Mortality With in Critically Ill COVID-19 Hemodilysis Patients: a Single-center Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200059730
Enrollment
Unknown
Registered
2022-05-10
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients with severe COVID-19

Interventions

Group 1 :CRRT
Group 2:CRRT combined with Cytokine Adsorption

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Hemodialysis patients aged >= 18 years; 2. Meet the definition of severe or critical new coronary pneumonia in the Ninth Edition of the National Health and Family Planning Commission's New Coronary Pneumonia Diagnosis and Treatment Guidelines; 3. Have received standard treatment including fluid resuscitation, vasoactive drugs, antibiotics, respiratory support, nutritional support, and vital sign monitoring (in accordance with the 2021 SSCM guidelines); 4. Patients and their families are informed, voluntarily participate in this study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are pregnant or suspected to be pregnant or breastfeeding at the time of enrollment; 2. Patients with extensive metastasis of malignant tumors; 3. Acute myocardial infarction in the past 4 weeks; 4. Combined with uncontrolled bleeding (acute bleeding > 3 UPC in the past 24 hours); 5. Patients with severe leukopenia (< 0.5 x 10^9/L) or severe thrombocytopenia (< 50 x 10^9/L); 6. Patients who are allergic to hemoperfusion devices and filters; 7. Those who are allergic to anticoagulants.

Design outcomes

Primary

MeasureTime frame
All-cause Mortality;

Secondary

MeasureTime frame
Inflammatory factor clearance rate;Mean arterial pressure;Dosage of vasoactive drugs;Sequential Organ Failure Assessment Score;Length of ICU Stay;Kidney function recovery;Sequential Organ Failure Assessment Score;Duration of vasoactive drug use;Duration of mechanical ventilation;

Countries

China

Contacts

Public ContactWang Niansong

Shanghai Sixth People's Hospital

wangniansong2012@163.com+86 18930177399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026